Evaluation of serum procalcitonin and C-reactive protein levels as biomarkers of Henoch-Schönlein purpura in pediatric patients

2014 ◽  
Vol 35 (3) ◽  
pp. 667-671 ◽  
Author(s):  
Xu Teng ◽  
Yang Wang ◽  
Nan Lin ◽  
Mei Sun ◽  
Jie Wu
2014 ◽  
Vol 60 (1) ◽  
pp. 269-271 ◽  
Author(s):  
Ali Kanik ◽  
Engin Kose ◽  
Masallah Baran ◽  
Seda Sirin Kose ◽  
Kayi Eliacik ◽  
...  

2021 ◽  
Vol 2021 ◽  
pp. 1-8
Author(s):  
Shuai Qin ◽  
Dan Li ◽  
Bo Zhang

By applying the PDCA model to the care of children with Henoch-Schonlein purpura, the nursing process can be divided into four stages: planning, execution, inspection, and treatment. According to the age characteristics and disease progression of pediatric patients, a complete nursing plan is formulated to efficiently implement the nursing content and improve the nursing effect. This paper studies the application of the PDCA nursing model in the nursing of children with Henoch-Schonlein purpura and statistically analyzes the disappearance of skin rash, joint pain relief, disappearance of urine protein, disappearance of gastrointestinal symptoms, etc. Finally, this paper combines the experiment to evaluate the intervention effect of this nursing model and provides reference for the follow-up care of children with Henoch-Schonlein purpura. From the results of experimental research, it can be known that PDCA nursing can improve the comfort of children with Henoch-Schonlein purpura, shorten the time for symptom disappearance, and speed up the recovery process.


2008 ◽  
Vol 35 (12) ◽  
pp. 2427-2429 ◽  
Author(s):  
Z. BÝRSÝN ÖZÇAKAR ◽  
FATOS YALÇINKAYA ◽  
NÝLGÜN ÇAKAR ◽  
BANU ACAR ◽  
ÖZGÜR KASAPÇOPUR ◽  
...  

ObjectiveTo investigate the prevalence of MEFV gene mutations in Turkish patients with Henoch-Schönlein purpura (HSP) but with no symptoms of familial Mediterranean fever (FMF). In addition, we assessed the clinical and laboratory characteristics of HSP patients with and without MEFV mutations.MethodsEighty pediatric patients with HSP (44 boys and 36 girls) were enrolled. Blood for mutation analysis was obtained either at the time of the diagnosis of HSP or during followup visits in previously diagnosed patients. No patient had the diagnosis of FMF in their history and in the followup period. Exon 10 of the MEFV gene was screened, together with p.E148Q mutation analysis.ResultsTwenty-seven (34%) patients were found to be heterozygous for one of the screened MEFV mutations; p.M694V in 16, p.M680I in 5, p.V726A in 3, and p.E148Q in 3 patients. Patients with MEFV mutations were younger than those without mutations and they had edema and arthritis more frequently. Also, the frequencies of elevated erythrocyte sedimentation rate and C-reactive protein values were found to be significantly higher in patients who had MEFV mutations.ConclusionAlterations in the MEFV gene are important susceptibility factors for the development of HSP and also affect the clinical presentation of it.


Author(s):  
Laura May Miles ◽  
Sofianne Gabrielli ◽  
Michelle Le ◽  
Elena Netchiporouk ◽  
Sharon Baum ◽  
...  

<b><i>Background:</i></b> Some forms of chronic urticaria (CU) can be specifically attributed to a response to a definite trigger, referred to as chronic inducible urticaria (CIndU). We aimed to assess the demographics, clinical characteristics, comorbidities, natural history, and management of pediatric patients with CIndU. <b><i>Methods:</i></b> Over a 6-year period, children presenting to the allergy clinic at the Montreal Children’s Hospital (MCH) with CIndU were prospectively recruited. CU was defined as the presence of wheals and/or angioedema, occurring for at least 6 weeks. A standardized diagnostic test was used to establish the presence of a specific form of urticaria. Resolution was defined as the absence of hives for 1 year without treatment. <b><i>Results:</i></b> Sixty-four patients presented with CIndU, of which 51.6% were male, with a median age of 12.5 (interquartile range 7.3, 15.9) years. Cold CU and cholinergic CU were the most common subtypes (60.3 and 41.3%, respectively). Basophil counts were undetectable in 48.4% of the cases, and C-reactive protein levels were elevated in 7.8% of patients. Of all cases, 71.4% were controlled with second-generation antihistamines. The resolution rate was of 45.3% (95% confidence interval 33.1–57.5%), based on per-protocol population within the 6-year course of the study. Resolution was more likely in patients who presented with well-controlled urticaria control test scores and elevated CD63 counts and in those suffering from thyroid comorbidity. <b><i>Conclusion:</i></b> The natural history of CIndU resolution in pediatric patients was relatively low and was associated with elevated CD63 levels, as well as thyroid comorbidity.


Sign in / Sign up

Export Citation Format

Share Document